Cargando…
Contezolid: First Approval
Contezolid 康替唑胺 (Youxitai 优喜泰(®)), an orally administered oxazolidinone antibacterial agent, is being developed by Shanghai MicuRx Pharmaceutical Co., Ltd. for the treatment of multidrug-resistant (MDR) Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA)...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536612/ https://www.ncbi.nlm.nih.gov/pubmed/34365606 http://dx.doi.org/10.1007/s40265-021-01576-0 |